Highly effective HCV-therapy and low rate of reinfection in persons who inject drugs and receive opioid agonist therapy

Raphael Schubert Head of Nursing Department - Suchthilfe Wien 9/7/2017 INHSU 2017, New York

Disclosures:

• A part of this project was supported by Gilead Sciences

• Raphael Schubert received congress and travel fees from Gilead Sciences

Characteristics of "difficult-to-treat patients" (= patients with "Borderline Compliance")

- History of or current intravenous drug use 1.
- Opioid agonist treatment (OAT) under stable conditions (on a daily 2. basis in a low threshold facility or pharmacy)
- By judgement of physicians: 3.

Highly unlikely that the patient would regulary ingest his/her tablets for HCV-treatment if they were handed to him/her for selfadministration at home.

 \rightarrow "Directly observed therapy": OAT and DAA's on a daily basis in pharmacy or low-threshold facility

"Directly observed therapy"

Low threshold facility - Suchthilfe Wien & about 40 pharmacies in Vienna





4

Compliance:	e: Virological Outcome:		
Adherence to therapy in the first 88 patients:	Baseline characteristics and virological outcome in the first 88 patients:		
 A total of only 15 scheduled dates for ingestion of therapy were missed by 88 patients = 0.17 dates per patient 	 male/female: mean age: GT 1/2/3/4: liver cirrhosis: SVR12: 	66/22 39.04 ± 8.9y 60/2/24/2 n = 26 88/88 (100%)	

Update: 29.08.2017 5

Reinfection-rate

Reinfections: 5/88 (5.7%)


Kaplan-Meier probability of being free of reinfection:

(Weeks after end of treatment)

12 weeks 9	7.7%
------------	------

- 24 weeks 95.0%
- 48 weeks 91.6%
- 72 weaks 01 00
- 72 weeks 91.6%





Conclusions

- The concept of "directly observed therapy" is highly effective in treatment of hepatitis C in PWID with "borderline compliance".
- Reinfection-rate is low, despite of continued intravenous drug use in a majority of these patients.
- By successful treatment of these patients further transmission of the virus may be prevented.

Acknowledgments to the Viennese HCV-Treatment Network

Wilhelminenspital 4th Department of Medicine	Stephan Moser Enisa Gutic Michael Gschwantler	EL V
Suchthilfe Wien Outpatient clinic	Angelika Schütz Raphael Schubert Cornelia Schwanke Hans Haltmayer	S
Verein Dialog	Doris Kalchbrenner Gerhard Rechberger	IND
Viennese Chamber of pharmacists	Andrea Vlasek Viktor Hafner	4











40 Pharmacies in Vienna and Lower Austria

8